TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab

  • STATUS
    Recruiting
  • participants needed
    36
  • sponsor
    PharmAbcine
Updated on 3 July 2022
measurable disease
karnofsky performance status
neutrophil count
immunohistochemistry
bevacizumab
aptt
thromboplastin
glioblastoma multiforme
gliosarcoma

Summary

This is a phase II, open-Label clinical trial to evaluate the safety and efficacy of TTAC-0001 in patients with recurrent glioblastoma who was progressed on bevacizumab including therapy.

Details
Condition Recurrent Glioblastoma
Treatment TTAC-0001
Clinical Study IdentifierNCT03856099
SponsorPharmAbcine
Last Modified on3 July 2022

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note